Target Price | $11.22 |
Price | $11.68 |
Deviation |
3.94%
register free of charge
|
Number of Estimates | 9 |
9 Analysts have issued a price target Aurinia Pharmaceuticals Inc. 2026 .
The average Aurinia Pharmaceuticals Inc. target price is $11.22.
This is
3.94%
register free of charge
$17.85
52.83%
register free of charge
$9.09
22.17%
register free of charge
|
|
A rating was issued by 12 analysts: 10 Analysts recommend Aurinia Pharmaceuticals Inc. to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Aurinia Pharmaceuticals Inc. stock has an average upside potential 2026 of
3.94%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 235.13 | 274.92 |
33.97% | 16.92% | |
EBITDA Margin | 16.10% | 36.30% |
135.31% | 125.44% | |
Net Margin | 2.45% | 32.24% |
105.50% | 1,218.36% |
8 Analysts have issued a sales forecast Aurinia Pharmaceuticals Inc. 2025 . The average Aurinia Pharmaceuticals Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Aurinia Pharmaceuticals Inc. EBITDA forecast 2025. The average Aurinia Pharmaceuticals Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Aurinia Pharmaceuticals Inc. Analysts have issued a net profit forecast 2025. The average Aurinia Pharmaceuticals Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 0.04 | 0.67 |
107.41% | 1,575.00% | |
P/E | 17.48 | |
EV/Sales | 4.72 |
8 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast for earnings per share. The average Aurinia Pharmaceuticals Inc. EPS is
This results in the following potential growth metrics and future valuations:
Aurinia Pharmaceuticals Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
RBC Capital |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Sep 16 2024 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Sep 09 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 06 2024 |
Analyst Rating | Date |
---|---|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 01 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Sep 16 2024 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Sep 09 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 06 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.